Edwards Lifesciences Corp (EW)vsNasdaq Inc (NDAQ)
EW
Edwards Lifesciences Corp
$79.96
-3.38%
HEALTHCARE · Cap: $47.71B
NDAQ
Nasdaq Inc
$88.91
-0.10%
FINANCIAL SERVICES · Cap: $50.28B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 16% more annual revenue ($6.30B vs $5.42B). NDAQ leads profitability with a 35.3% profit margin vs 17.4%. EW appears more attractively valued with a PEG of 2.04. NDAQ earns a higher WallStSmart Score of 69/100 (B-).
EW
Buy61
out of 100
Grade: C+
NDAQ
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.7%
Fair Value
$261.90
Current Price
$79.96
$181.94 discount
Intrinsic value data unavailable for NDAQ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 31.2%
16.7% revenue growth
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 48.4%
Large-cap with strong market position
Earnings expanding 33.8% YoY
Areas to Watch
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Comparative Analysis Report
WallStSmart ResearchBull Case : EW
The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bull Case : NDAQ
The strongest argument for NDAQ centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 35.3% and operating margin at 48.4%. Revenue growth of 13.7% demonstrates continued momentum.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 44.7x leaves little room for execution misses.
Bear Case : NDAQ
The primary concerns for NDAQ are PEG Ratio, P/E Ratio.
Key Dynamics to Monitor
EW profiles as a growth stock while NDAQ is a mature play — different risk/reward profiles.
NDAQ carries more volatility with a beta of 0.99 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
NDAQ generates stronger free cash flow (629M), providing more financial flexibility.
Bottom Line
NDAQ scores higher overall (69/100 vs 61/100), backed by strong 35.3% margins and 13.7% revenue growth. EW offers better value entry with a 69.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Nasdaq Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
Nasdaq, Inc. is an American multinational financial services corporation that owns and operates stock exchanges in the United States and Europe. It is headquartered in New York City.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?